Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sarepta Therapeutics Inc (SRPT) Gets Off To A Running Start With Eteplirsen

Sarepta Therapeutics Inc (NASDAQ:SRPT) ­is one of the week’s biggest winners from the J.P. Morgan healthcare conference, with the company running up on the back of a CEO presentation which – for the most part – focused on the launch progress of the company’s Duchenne’s muscular dystrophy (DMD) asset, Eteplirsen. The company is now calling the drug Exondys 51 (don’t ask us why, for us, Eteplirsen was a pretty solid name) and so for the purposes of this discussion, we will refer to it by its brand name going forward.

Those familiar with the history of this one will know that the company had a pretty tough time getting Exondys 51 past the FDA. Basically, the clinical benefit was negligible, as implied by a host of highly publicized clinical trials, and this led a number of opinion leaders to suggest that the drug shouldn’t be approved. However, it was proven safe, and there is no currently available alternative for DMD sufferers. Further, when it came to the advisory panel, there was a large showing by the DMD community – parents, sufferers, advocates etc. – all bidding to get the drug approved, despite its negligible benefit.

gene, dna, organism, microarray, health, green, life, human genome, biotechnology, genetic diseases, disease, molecular biology, modern medical, micro structure,

Yang Nan/Shutterstock.com

Anyway, when it came down to it, the drug picked up approval, and Sarepta got to marketing it right away. Ironically, but beneficially, the uncertainty surrounding the approval actually served to provide some pretty far-reaching (and completely free) marketing for Sarepta within the DMD community. Many expected that this would help get the drug off to a running start, and this seems to have been proven accurate.

Before we get into the numbers, it is worth pointing out that there was also some degree of concern over whether the insurance industry in the US would cover the drug. Anthem Inc (NYSE:ANTM) refused to, and concerns that other big insurers would follow suit weighed on sentiment heading into the first quarter of sales. With company CEO Ed Kaye having taken the stage at J.P. Morgan, however, these concerns seem to have disappeared, or at least, have been allayed.

During the fourth quarter of 2016, sales for the drug hit $5.4 million, and there are more than 250 patients for which start forms have been submitted. Start forms are basically the document a physician must submit when he or she first starts prescribing the drug to an individual. 250 patients may not sound like a lot, but for a drug the costs $300,000 annually, it is pretty substantial.

Also addressed was the insurance situation. Most of the patients currently taking the drug are covered by insurance, be it commercial or Medicaid, and – according to the CEO – nearly 80% of commercial insurers have not yet decided whether to cover the drug or not. Chances are these insurers are watching early uptake numbers closely, and with the 250 start forms in place, and the decent (albeit not excellent) fourth-quarter sales numbers, many of these 80% will likely be leaning towards accepting the drug for coverage going forward.

So what is next? Well, having gotten off to a pretty decent start in the US, Sarepta Therapeutics Inc (NASDAQ:SRPT) must now turn its focus to the European market, in an attempt to replicate the FDA’s decision on the drug with the EMA. This will essentially double the market potential of Exondys 51, and in a condition whereby there aren’t that many sufferers (DMD is classed as a rare disease in both Europe and the US) the wider potential population over which Sarepta can throw its Exondys net, the better the chances of the company turning a profit on this drug are.

From a near-term perspective, we are looking for any news on insurers – and their coverage decisions – as potential catalysts. If the company can pick up some big names on its coverage roster, and we have no doubt that it will, then there is some immediate upside from the announcement of such. Similarly, however, and herein lies the risk, there’s definitely some downside on any big insurers deciding – and publishing the fact that – they aren’t willing to cover Exondys.

All said, the J.P. Morgan conference has proven a sentiment shifter for Sarepta Therapeutics Inc (NASDAQ:SRPT) in many regards, and will likely be considered a success by the retail markets going forward into the first quarter of 2017, and beyond.

One to keep an eye on.

Follow Sarepta Therapeutics Inc. (NASDAQ:SRPT)
Trade (NASDAQ:SRPT) Now!

Note: This article is written by Mark Collins and was originally published at Market Exclusive.

Loading Comments...